GRAL
Price:
$104.705
Market Cap:
$3.66B
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Industry
Medical - Diagnostics & Research
IPO Date
2024-06-12
Stock Exchange
NASDAQ
Ticker
GRAL
According to GRAIL, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -9.82. This represents a change of 191.31% compared to the average of -3.37 of the last 4 quarters.
The mean historical PE Ratio of GRAIL, Inc. over the last ten years is -2.70. The current -9.82 PE Ratio has changed 36.22% with respect to the historical average. Over the past ten years (40 quarters), GRAL's PE Ratio was at its highest in in the June 2024 quarter at -0.07. The PE Ratio was at its lowest in in the December 2023 quarter at -19.30.
Average
-2.70
Median
-0.34
Minimum
-6.87
Maximum
-0.08
Discovering the peaks and valleys of GRAIL, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 268.37%
Maximum Annual PE Ratio = -0.08
Minimum Annual Increase = -93.72%
Minimum Annual PE Ratio = -6.87
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -0.28 | -2.93% |
| 2023 | -0.29 | 268.37% |
| 2022 | -0.08 | -76.89% |
| 2021 | -0.34 | -93.72% |
| 2020 | -5.41 | -21.26% |
| 2019 | -6.87 | 21.53% |
The current PE Ratio of GRAIL, Inc. (GRAL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-0.22
5-year avg
-1.28
10-year avg
-2.70
GRAIL, Inc.’s PE Ratio is less than Dyne Therapeutics, Inc. (-5.70), less than Ultragenyx Pharmaceutical Inc. (-6.29), greater than Apogee Therapeutics, Inc. (-17.49), greater than Xenon Pharmaceuticals Inc. (-12.66), greater than Centessa Pharmaceuticals plc (-17.15), less than Envista Holdings Corp (222.61), greater than ASCENTAGE PHARMA GROUP INTERNATIONAL (-63.93), greater than Celcuity Inc. (-29.14), greater than Soleno Therapeutics, Inc. (-35.81), less than IDEAYA Biosciences, Inc. (-9.62),
| Company | PE Ratio | Market cap |
|---|---|---|
| -5.70 | $2.95B | |
| -6.29 | $3.52B | |
| -17.49 | $4.14B | |
| -12.66 | $3.45B | |
| -17.15 | $3.97B | |
| 222.61 | $3.31B | |
| -63.93 | $2.85B | |
| -29.14 | $4.90B | |
| -35.81 | $2.83B | |
| -9.62 | $3.16B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GRAIL, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like GRAIL, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is GRAIL, Inc.'s PE Ratio?
How is the PE Ratio calculated for GRAIL, Inc. (GRAL)?
What is the highest PE Ratio for GRAIL, Inc. (GRAL)?
What is the 3-year average PE Ratio for GRAIL, Inc. (GRAL)?
What is the 5-year average PE Ratio for GRAIL, Inc. (GRAL)?
How does the current PE Ratio for GRAIL, Inc. (GRAL) compare to its historical average?